PMID- 37948350
OWN - NLM
STAT- MEDLINE
DCOM- 20240228
LR  - 20240228
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 35
IP  - 3
DP  - 2024 Mar 1
TI  - Efficacy and safety of sintilimab combined with apatinib as third-line or above 
      therapy for patients with advanced or metastatic gastric cancer.
PG  - 277-283
LID - 10.1097/CAD.0000000000001554 [doi]
AB  - This study aimed to evaluate the efficacy and safety of the combination of 
      sintilimab and apatinib for the treatment of patients with advanced or metastatic 
      gastric cancer (GC) and gastroesophageal junction (GEJ) cancer. This 
      retrospective study analyzed data from 34 patients who had advanced or metastatic 
      GC/GEJ cancer and received the combination therapy of sintilimab and apatinib as 
      a third-line or above treatment. The primary endpoint was progression-free 
      survival (PFS), and secondary endpoints included objective response rate (ORR), 
      disease control rate (DCR), overall survival (OS), and safety. Among the 34 
      patients, none achieved a complete response (CR), 3 patients (8.8%) achieved a 
      partial response, 23 patients (67.6%) had stable disease, and 8 patients (23.5%) 
      experienced progressive disease. The ORR and DCR were 8.8% and 76.5%, 
      respectively. The median PFS was 6.0 months (95% CI: 3.6-8.4), and the median OS 
      was 11.6 months (95% CI: 8.1-15.1). Subgroup analysis revealed significant 
      differences in OS between patients with high and low Eastern Cooperative Oncology 
      Group Performance Status scores and between patients with and without a history 
      of gastrectomy. Common adverse events (AEs) during treatment included fatigue 
      (52.9%), anemia (47.1%), leukopenia (26.5%), hypothyroidism (23.5%), nausea and 
      vomiting (20.6%), neutropenia (20.6%), and thrombocytopenia (17.6%), most of 
      which were grade 1 and 2 AEs. No deaths occurred due to AEs. These findings 
      indicate that the combination of sintilimab and apatinib has a favorable 
      therapeutic effect in patients with advanced GC. Moreover, the AEs associated 
      with this therapy are generally manageable.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Gao, Loulu
AU  - Gao L
AD  - School of Clinical Medicine, Weifang Medical University, Weifang.
AD  - Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First 
      Medical University and Shandong Academy of Medical Sciences.
FAU - Tang, Lin
AU  - Tang L
AD  - Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First 
      Medical University and Shandong Academy of Medical Sciences.
AD  - Department of Oncology, Shandong First Medical University and Shandong Academy of 
      Medical Sciences, Jinan, China.
FAU - Li, Xiaoqian
AU  - Li X
AD  - Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First 
      Medical University and Shandong Academy of Medical Sciences.
FAU - Peng, Jieqiong
AU  - Peng J
AD  - Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First 
      Medical University and Shandong Academy of Medical Sciences.
FAU - Hu, Zixuan
AU  - Hu Z
AD  - School of Clinical Medicine, Weifang Medical University, Weifang.
FAU - Liu, Bo
AU  - Liu B
AD  - Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First 
      Medical University and Shandong Academy of Medical Sciences.
LA  - eng
PT  - Journal Article
DEP - 20231113
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 5S371K6132 (apatinib)
RN  - 8FU7FQ8UPK (sintilimab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Pyridines)
SB  - IM
MH  - Humans
MH  - *Stomach Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Antibodies, Monoclonal, Humanized
MH  - *Splenic Neoplasms
MH  - *Esophageal Neoplasms
MH  - *Pyridines
PMC - PMC10833188
COIS- There are no conflicts of interest.
EDAT- 2023/11/10 18:43
MHDA- 2024/02/28 06:43
PMCR- 2024/02/01
CRDT- 2023/11/10 13:24
PHST- 2024/02/28 06:43 [medline]
PHST- 2023/11/10 18:43 [pubmed]
PHST- 2023/11/10 13:24 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - 00001813-990000000-00221 [pii]
AID - 10.1097/CAD.0000000000001554 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2024 Mar 1;35(3):277-283. doi: 10.1097/CAD.0000000000001554. 
      Epub 2023 Nov 13.